Structure Therapeutics Inc. Net Income (Loss) Available to Common Stockholders, Basic
Structure Therapeutics Inc. (GPCR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$33.98 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-13
- Structure Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$33.98M.
- Structure Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$26.03M.
- Structure Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$26.04M.
- Structure Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$24.50M.
- Structure Therapeutics Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$89.62M.
- Structure Therapeutics Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$52.84M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$33.98M 10-Q · filed 2024-11-13 | -$60.01M derived: sum of 2 quarters · filed 2024-11-13 | -$86.05M 10-Q · filed 2024-11-13 | -$110.55M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | -$26.03M 10-Q · filed 2024-08-08 | -$52.07M 10-Q · filed 2024-08-08 | -$76.57M derived: sum of 3 quarters · filed 2024-08-08 | -$100.44M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | -$26.04M 10-Q · filed 2024-05-09 | -$50.54M derived: sum of 2 quarters · filed 2024-05-09 | -$74.40M derived: sum of 3 quarters · filed 2024-11-13 | -$97.68M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | -$24.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$48.37M derived: sum of 2 quarters · filed 2024-11-13 | -$71.64M derived: sum of 3 quarters · filed 2024-11-13 | -$89.62M 10-K · filed 2024-03-08 |
| 2023-09-30 | -$23.86M 10-Q · filed 2024-11-13 | -$47.14M derived: sum of 2 quarters · filed 2024-11-13 | -$65.12M 10-Q · filed 2024-11-13 | -$76.99M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$23.28M 10-Q · filed 2024-08-08 | -$41.26M 10-Q · filed 2024-08-08 | -$53.13M derived: sum of 3 quarters · filed 2024-08-08 | -$65.55M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$17.98M 10-Q · filed 2024-05-09 | -$29.85M derived: sum of 2 quarters · filed 2024-05-09 | -$42.27M derived: sum of 3 quarters · filed 2024-05-09 | -$57.73M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$11.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$24.29M derived: sum of 2 quarters · filed 2024-03-08 | -$39.76M derived: sum of 3 quarters · filed 2024-03-08 | -$52.84M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$12.42M 10-Q · filed 2023-11-17 | -$27.88M derived: sum of 2 quarters · filed 2023-11-17 | -$40.96M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | -$15.46M 10-Q/A · filed 2023-11-17 | -$28.54M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$13.08M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |